From the archive1 min read
Efficacy and safety of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease
Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and…
Scientific Articles · Comorbidities · Disease Management · Hepatitis C · Ledipasvir · Others · Pharmacotherapy/Drug Therapy · Sofosbuvir
About this article
- Source:
- oneSCDvoice(opens in a new tab)
- Published
oneSCDvoice
Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed dose combination, ledipasvir and sofosbuvir for 12 weeks in this population.
Abstract source
Full text